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Abstract
Background: Insulin receptor substrate (IRS) proteins are key moderators of insulin action. Their
specific regulation determines downstream protein-protein interactions and confers specificity on
growth factor signalling. Regulatory mechanisms that have been identified include phosphorylation
of IRS proteins on tyrosine and serine residues and ubiquitination of lysine residues. This study
investigated other potential molecular mechanisms of IRS-1 regulation.
Results: Using the sos recruitment yeast two-hybrid system we found that IRS-1 and histone
deacetylase 2 (HDAC2) interact in the cytoplasmic compartment of yeast cells. The interaction
mapped to the C-terminus of IRS-1 and was confirmed through co-immunoprecipitation in vitro of
recombinant IRS-1 and HDAC2. HDAC2 bound to IRS-1 in mammalian cells treated with phorbol
ester or after prolonged treatment with insulin/IGF-1 and also in the livers of ob/ob mice but not
PTP1B knockout mice. Thus, the association occurs under conditions of compromised insulin
signalling. We found that IRS-1 is an acetylated protein, of which the acetylation is increased by
treatment of cells with Trichostatin A (TSA), an inhibitor of HDAC activity. TSA-induced increases
in acetylation of IRS-1 were concomitant with increases in tyrosine phosphorylation in response to
insulin. These effects were confirmed using RNA interference against HDAC2, indicating that
HDAC2 specifically prevents phosphorylation of IRS-1 by the insulin receptor.
Conclusions:  Our results show that IRS-1 is an acetylated protein, a post-translational
modification that has not been previously described. Acetylation of IRS-1 is permissive for tyrosine
phosphorylation and facilitates insulin-stimulated signal transduction. Specific inhibition of HDAC2
may increase insulin sensitivity in otherwise insulin resistant conditions.
Background
The insulin receptor substrate (IRS) proteins represent key
elements in insulin and insulin-like growth factor (IGF)
actions, transducing pleiotropic effects on cellular func-
tion and regulating processes such as metabolism, growth,
cell differentiation and survival [1]. At least four members
(IRS 1–4) have been identified that differ with regard to
tissue distribution, subcellular localization, developmen-
tal expression, binding to the insulin receptor, and inter-
action with Src homology 2 (SH2) domains. They are all
structurally characterised by N-terminal pleckstrin-
homology (PH) and phosphotyrosine-binding (PTB)
domains, which are required for coupling to the activated
insulin/IGF receptors, and a C-terminal region with mul-
tiple sites for tyrosine phosphorylation by the receptors.
IRS proteins thus act as molecular adapters in recruiting,
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inter alia, a number of SH2-containing proteins binding to
specific phosphorylated tyrosine residues. This leads to
activation of different intracellular cascades [2], one of
which is the PI 3-kinase signalling cascade implicated in
mediating the metabolic effects of insulin [3].
The best-substantiated post-translational modification of
IRS proteins, in addition to tyrosine phosphorylation, is
phosphorylation of specific serine residues. Phosphoryla-
tion on these residues is associated both with inhibition
of insulin-induced tyrosine phosphorylation of IRS pro-
teins and with facilitation of the effects of insulin [4].
Phosphorylation catalysed by protein kinase C (PKC) iso-
zymes [5,6], c-Jun N-terminal kinase (JNK) [7], inhibitor
κB kinase (IKK) isozymes [8], mitogen activated protein
kinases (MAPK) [9] and the mammalian target of rapamy-
cin (mTOR) [10] are all associated with reducing the abil-
ity of insulin to stimulate tyrosine phosphorylation of IRS
proteins and therefore may be part of the physiological
and pathophysiological negative regulation of insulin sig-
nalling through the IRS pathway. Specific mechanisms
explaining why serine phosphorylation leads to reduced
tyrosine phosphorylation have not been completely iden-
tified, but candidates for this are reduced interaction of
IRS proteins with the insulin receptor [11] and increased
degradation of IRS [12,13]. Furthermore, phosphoryla-
tion of different residues can lead to different effects.
Thus, phosphorylation of serine 307 in rat IRS-1 (serine
312 in human IRS-1) is associated with reduced insulin
signalling [7] whilst phosphorylation of serine 302 has
recently been suggested to facilitate insulin signalling
[14], although this has been contested [15].
In addition to phosphorylation of different amino acid
residues, insulin signalling through IRS proteins has been
shown to be regulated by at least two other mechanisms.
Prolonged signal transduction via phosphoinositide 3-
kinase (PI3K), which generates the lipid second messen-
ger phosphatidylinositol 3,4,5-trisphosphate, has been
shown to induce a state of insulin resistance in cells [16],
in part through degradation of IRS-1 [17]. Thus, insulin
signalling can be negatively regulated through modula-
tion of IRS concentrations in cells, via degradation of the
proteins in the proteasomal pathway [18-20]. The mecha-
nism by which IRS proteins are degraded by the proteas-
ome is not completely understood, but the N-terminal PH
and PTB domains are required [21]. In addition, the sub-
cellular localisation of IRS proteins may be important for
appropriate insulin signalling. The sub-cellular localisa-
tion is not absolutely defined, with various lines of evi-
dence pointing to potential places in the cell where the
proteins can be found. In addition to the plasma mem-
brane, IRS proteins have been associated with high-den-
sity pellets [22] implicating association with the
cytoskeleton and recently also with the nucleus [23,24].
Thus, IRS proteins may be located to different parts of the
cell where they carry out different functions.
Multiple histone acetyltransferases (HATs) and histone
deacetylases (HDACs) control the state of histone acetyla-
tion and hence play a regulatory role in modulating the
structure and function of chromatin [25]. About 20 HATs
have been detected to date, grouped in three different
classes on the basis of structural properties. They all have
one structural motif in common, the so-called A-motif
responsible for acetyl CoA recognition [25]. Several HATs
also have non-histone substrates but it is not yet possible
to identify putative acetylation sites within a protein sim-
ply by sequence analysis. Generally, acetylation affects
DNA-binding, protein-protein interactions, protein sta-
bility, and protein localization [26]. The acetyl-mediated
signals are reversed by HDACs that counteract the effects
of HATs by deacetylating lysine residues on histone tails.
In higher eukaryotes, HDACs can be subdivided into three
distinct groups known as classes I, II, III, according to sim-
ilarities of their sequences to those of yeast founding
members [27]. To date, four enzymes, HDAC1, 2, 3 and 8,
are the known members of class I deacetylases [28,29].
HDAC1 and 2 are the best characterised, and are chief
constituents of the multiprotein transcriptional-repres-
sion complex Sin3/HDAC and the nucleosome remodel-
ling deacetylase NuRD/Mi2/NRD complex [30].
Complexes that contain class I HDACs bind to numerous
transcription factors, either directly, or indirectly through
the nuclear-hormone corepressors NCOR and SMRT
(silencing mediator for retinoid and thyroid hormone
receptors). Although all class I and II HDACs can
deacetylate histone tails, other cellular proteins can be
specifically targeted by different HDACs as well, such as α-
tubulin and importin-α [31]. Recent developments have
shown that the class I enzymes are regulated by phospho-
rylation, by casein kinase II amongst others, which
increases activity [32-34]. The fact that class II enzymes are
phosphorylated has been known for longer, a reaction
which is associated with re-localization of the enzymes to
the cytoplasm through interactions with 14-3-3 proteins
[35].
We now demonstrate that HDAC2 interacts with IRS-1
under conditions when the ability of cells to respond to
insulin is compromised. As such, this interaction may
constitute a new component of the negative regulation of
IRS protein function. We also show that IRS-1 is
acetylated, and that augmenting the acetylation level by
treating cells with Trichostatin A (TSA, a non-specific
inhibitor of HDACs) or with short inhibitory RNA oligo-
nucleotides against HDAC2 partially restores normal
responsiveness to insulin.BMC Biology 2004, 2:23 http://www.biomedcentral.com/1741-7007/2/23
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Results and discussion
Interaction between IRS-1 and HDAC2
In an attempt to elucidate the regulation of IRS-1, we
investigated inter-molecular interactions between IRS-1
and potential binding partners using yeast two-hybrid
screening through a human foetal brain plasmid cDNA
library. The system we used was the sos recruitment sys-
tem as described in the Methods section, which displays
protein-protein interactions in the cytoplasm of yeast
cells. In these experiments, full length human IRS-1 was
used as bait. Two independent transformants from a
screen of 4 × 105 cDNAs encoded the N-terminal portion
of a 488 amino acid protein identified as histone deacety-
lase 2 (HDAC2, Figure 1A).
To map the interaction site of HDAC2 on IRS-1 we used a
GAL4-based yeast two-hybrid system, where interactions
take place in the nucleus of the yeast cell. Cells were trans-
formed with vectors encoding full length HDAC2 and dif-
ferent truncation mutants of IRS-1. The truncations of IRS-
1 that were used were the PH domain (residues 1–155),
the PH-PTB domains (residues 1–578) and the PH-PTB-
pre-C-terminal domains (residues 1–895). Using growth
of yeast cells on selective medium as a readout for interac-
tion between HDAC2 and IRS-1 showed that the interac-
tion requires the C-terminal portion of the IRS-1 protein
(Figure 1B). In order to confirm the interaction further in
vitro, we used a coupled in vitro transcription/translation
system in which full length IRS-1 and the HDAC2 N-ter-
minal portion from the initial yeast two-hybrid screen
were transcribed and translated in the presence of S35
methionine. IRS-1 was subsequently immunoprecipitated
from the mixture and the proteins were resolved by SDS-
PAGE. Gels were then subjected to autoradiography.
Results showed that two radioactive protein bands were
visible in the IRS-1 immunoprecipitates (Figure 1C) and
their molecular weights corresponded to those of full
length IRS-1 (approx 160 kD) and truncated HDAC2
(approx 35 kD). When the IRS-1 antibody was boiled
prior to immunoprecipitation (Figure 1C lane 2) or omit-
ted (Figure 1C lane 3), no radioactive proteins were
observed, indicating that the interaction between the two
proteins is specific and not due to non-specific interac-
tions with immunoglobulins or beads. Thus, IRS-1 and
HDAC2 proteins are able to interact with each other in
cell-free systems.
To validate the interaction between IRS-1 and HDAC2 fur-
ther and to ascertain whether IRS-1 and HDAC2 are asso-
ciated in mammalian systems, we chose to work with
MCF-7 cells (a human breast adenocarcinoma cell line),
with a high endogenous expression of IRS-1 [36]. The cells
were stimulated with IGF-1 or PMA (phorbol myristic
acid; a PKC activator known to inhibit growth factor sig-
nalling [37]) for different time periods. Immunoprecipita-
tions with IRS-1 antibody revealed that HDAC2 was co-
precipitated to a larger extent in PMA-treated cells (Figure
2A). In addition, the interaction between IRS-1 and
HDAC2 was more visible in cells under prolonged stimu-
lation with IGF-1. Similar results were obtained during
prolonged stimulation with insulin. Considering that the
ability of cells to respond to insulin and IGF-1 is reduced
after prolonged ligand stimulation or PMA treatment,
these data indicate that IRS-1 and HDAC2 associate when
responsiveness is low and intracellular serine phosphor-
ylation is increased. Indeed, analysis of serine phosphor-
ylation of IRS-1 after treatment of cells with insulin or
phorbol ester showed that PMA treatment caused a signif-
icant increase in phosphorylation of IRS1 on serine 312
(equivalent to serine 307 in rat IRS-1), which has been
associated with reduced phosphorylation on tyrosine res-
idues by the insulin receptor (Figure 2B lanes 1,2 and 4),
whereas insulin stimulation had no effect. In these exper-
iments, cells were stimulated with insulin for 10 minutes
and responsiveness was subsequently analysed by meas-
uring tyrosine phosphorylation of IRS-1 (see Figure 4 and
discussion below). Responsiveness of the cells to insulin
was compromised after PMA treatment, thus confirming
the apparent association of IRS-1 with HDAC2 under con-
ditions of reduced cellular sensitivity to insulin.
To assess whether the interaction measured between IRS-
1 and HDAC2 in vitro as described above occurs in vivo, we
prepared lysates of liver tissues prepared from different
mouse lines. The ob/ob mouse, which lacks functional
leptin, was chosen as an insulin resistant animal model,
and C57/bl6 was used as its genotype control. A PTP1B
knockout mouse [38] was used as an insulin-sensitised
animal model and balb/cJJ was used as its genotype con-
trol. IRS-1 was immunoprecipitated from liver lysates and
western blotted for co-immunoprecipitation of HDAC2.
The data showed that whilst a clear interaction between
IRS-1 and HDAC2 was seen in livers from ob/ob mice
(Figure 2C), no interaction was evident in the C57/bl6
control. In contrast, no interaction was evident in livers of
PTP1B knockout animals, whilst the balb/cJJ genotype
control demonstrated a measurable interaction. Taken
together with the in vitro data, these results showed that
IRS-1 and HDAC2 are able to interact with each other in
the cytoplasmic compartment of cells and that the interac-
tion occurs under conditions of reduced insulin sensitiv-
ity, both in mammalian cells and in animals. The
cytoplasmic location of the interaction is interesting in
view of the fact that HDAC2 is considered to be largely a
nuclear protein. In our work with cells and tissues, we
have utilised lysis methods that are designed to retain
nuclei intact and thereby minimise cross-contamination
of compartments [39,40]. Whilst we have not formally
excluded the possibility of contamination of cytoplasmic
extracts with nuclear lysate, thereby leading to theBMC Biology 2004, 2:23 http://www.biomedcentral.com/1741-7007/2/23
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Analysis of the interaction between IRS-1 and HDAC2 in vitro Figure 1
Analysis of the interaction between IRS-1 and HDAC2 in vitro. A: A human foetal brain plasmid cDNA library con-
tained in the p-myr vector was transformed into yeast cdc25 h cells containing full length IRS-1 in the pSos vector. Cell growth 
at the non-permissive temperature (37°C) on galactose medium (GAL 1 promoter in the library vector) was observed only in 
the presence of both IRS-1 and HDAC2 from the library from two independent transformants, which both encoded human 
HDAC2. B: Full length HDAC2 and different sub-cloned domains of IRS- 1 were used in the Matchmaker-3 yeast two-hybrid 
system to map the interaction between HDAC2 and IRS-1. Growth on medium lacking two nutritional markers was analysed 
to confirm interactions between predator and prey. C: Recombinant human IRS-1 and HDAC2 were transcribed and trans-
lated in vitro individually using a rabbit reticulocyte lysate as described in the Methods section. Proteins were then mixed and 
IRS-1 was immunoprecipitated from the solution (lane 1). As controls for the immunoprecipitation, the IRS-1 antibody was 
denatured by boiling prior to immunoprecipitation (lane 2) or all antibodies were omitted and beads alone were used (lane 3). 
Proteins were resolved by SDS-PAGE, the gel was dried and immunoprecipitated proteins were analysed by phosphorimagery. 
Protein bands matched IRS-1 (approx 160 kD) and truncated HDAC2 (approx. 35 kD).
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Analysis of conditions for interaction between IRS-1 and HDAC2 in mammalian cells and tissues Figure 2
Analysis of conditions for interaction between IRS-1 and HDAC2 in mammalian cells and tissues. A: MCF-7 
human breast carcinoma cells were treated with 10 ng/ml IGF-1 ("I") or 10 ng/ml PMA for the indicated times. IRS-1 was immu-
noprecipitated from cell lysates and western blots were analysed for co-immunoprecipitation of HDAC2. The upper gel shows 
presence of HDAC2 whilst the lower gel is a loading control for IRS-1. The data are representative of multiple experiments. 
Similar data are obtained if IGF-1 is exchanged for 100 nM insulin. B: MCF-7 cells were treated PMA (10 ng/ml) or TSA (150 
ng/ml) for 4 hours prior to stimulation with or without insulin (100 nM) for 10 minutes, lysis and immunoprecipitation of IRS-
1. Western blots were probed for the presence of phospho-serine 312 in IRS-1 (upper gel) and IRS-1 (lower gel). The histo-
gram shows the means ± range for results for serine 312 phosphorylation from two independent experiments, normalised to 
the maximum phosphorylation signal, which was seen in cells treated with PMA and TSA. In separate control experiments, we 
have seen that the phosphorylation of serine 312 in cells is driven by PMA and that TSA does not contribute to the effect (data 
not shown). C: Liver tissues from ob/ob mice, c57/bl6 mice, PTP1B knockout mice and balb/cjj mice were prepared as 
described in the Methods section and IRS-1 was immunoprecipitated. Western blots were analysed for the presence of 
HDAC2 (upper gel) or IRS-1 (lower gel). Each lane is from one mouse and is representative of at least two other animals per 
group.
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presence of HDAC2, we feel that the body of evidence
indicates that cytoplasmic HDAC2 is interacting with
cytoplasmic IRS-1 in our experiments. The yeast two
hybid "Sos recruitment system" is built on the rescue of
cell growth through the interaction of proteins in the cyto-
plasm, which is how we detected this interaction. Interest-
ingly, it has recently been shown that histone deacetylase
1, another class I histone deacetylase, which was consid-
ered to be exclusively nuclear, is present in a cytoplasmic
protein complex by virtue of interaction with a cellular
phosphatase complex [41].
Lysine acetylation of IRS-1 and insulin signal transduction
The finding that HDAC2 binds to IRS-1 indicated that IRS-
1 might be an acetylated protein in which acetylation
might be a regulated post-translational modification of
the protein. Indeed, the acetyl transferase Tip60 has been
reported to bind to the PH domain of IRS-1 [42], suggest-
ing the IRS-1 could be acetylated and deacetylated under
different conditions. The lysine-acetylation status of IRS-1
was assessed by western blotting of IRS1 immunoprecipi-
tated from MCF-7 cells after different treatments, using an
antibody specific for acetylated lysine. Trichostatin A
(TSA), which is a non-selective inhibitor of both class I
and class II HDACs [43], was used as a positive control.
Basal acetylation of the IRS1 protein was evident in
unstimulated cells (Figure 3). Stimulation of cells with
IGF-1 did not alter the level of acetylation although the
basal signal was low and small effects cannot therefore be
ruled out. PMA was also ineffective in altering the basal
degree of acetylation of IRS1 whereas treatment of cells
with TSA caused a very large increase in signal (Fig. 3).
Our data therefore show that IRS-1 protein is acetylated
on lysine residues, and the acetylation increases when
HDAC activity is generally inhibited. This represents a
heretofore-undescribed post-translational modification
of IRS1 in addition to tyrosine/serine phosphorylation
and ubiquitination previously described. TSA treatment
did not induce phosphorylation of IRS1 on serine 312
(Fig 2B lane 3), nor did it modify the increase in serine
312 phosphorylation in the presence of PMA (lanes 1 and
2).
The regulation and function of proteins such as sterol reg-
ulatory element binding protein 1c (SREBP1c) [44] and
p53 [45] has been shown to be altered by changes in
acetylation. The alterations in lysine acetylation in IRS-1
induced by TSA raised the possibility that insulin signal
transduction may be altered in cells after treatment with
IRS-1 is a lysine acetylated protein Figure 3
IRS-1 is a lysine acetylated protein. MCF-7 cells were 
treated with IGF-1 (10 ng/ml) for the indicated times, PMA 
(10 ng/ml) for 4 or 6 hours as indicated or TSA (150 ng/ml) 
for 4 hours prior to lysis and immunoprecipitation of IRS-1 
Western blots were probed for the presence of acetyl lysine. 
Densitometric analysis of acetylated IRS-1 was performed 
and is displayed in the histogram. This experiment has been 
repeated one other time although the effects of TSA on 
acetylation of IRS-1 have been observed in many other 
experiments.
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Increases in IRS-1 lysine acetylation enhance insulin signalling  to IRS-1 Figure 4
Increases in IRS-1 lysine acetylation enhance insulin 
signalling to IRS-1. MCF-7 cells were treated with PMA 
and/or TSA for 4 hours (concentrations as in Figure 3) prior 
to stimulation with 100 nM insulin for 10 minutes. IRS-1 was 
immunoprecipitated and blotted for the presence of phos-
photyrosine. The graph summarises results from 3 experi-
ments (± SEM) normalised to the response to insulin 
stimulation alone.
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this compound. To assess the effects of changes in IRS-1
acetylation on insulin signalling, MCF-7 cells were treated
with PMA, TSA and insulin in different combinations and
immunoprecipitated IRS-1 protein was immunoblotted
for the presence of phosphotyrosine. PMA alone and in
combination with TSA did not increase tyrosine phospho-
rylation of IRS1 above basal, as expected (Fig 4 lanes 4–6).
Furthermore, the ability of insulin to induce tyrosine
phosphorylation of IRS-1 was reduced by 60% in cells
pre-treated with PMA (Fig 4 lane 3) consistent with a state
of insulin unresponsiveness. However, pre-treatment with
TSA in the presence of PMA reduced this unresponsive-
ness, increasing insulin-stimulated tyrosine phosphoryla-
tion to 70% of control (Fig 4 lane 2). Thus, increases in
IRS1 acetylation via TSA-mediated HDAC inhibition were
able to restore insulin signalling significantly. This resto-
ration occurred without reducing PMA-induced serine
312 phosphorylation of IRS-1 (Fig 2B lane 2), indicating
that acetylation of IRS1 overcomes the inhibitory effects
of phosphorylation of serine 312.
To assess the relative roles of altered intracellular protein
acetylation and binding of HDAC2 to IRS-1 on insulin sig-
nalling, we treated cells with the general HAT inhibitor,
desulfo coenzyme A (DesCoA, [46]) and examined
HDAC2-IRS-1 interactions and insulin-stimulated tyro-
sine phosphorylation of IRS-1. The data showed that treat-
ment with DesCoA induced HDAC2 to bind to IRS-1 to a
similar extent to phorbol ester, which was coincident with
reduced insulin-stimulated tyrosine phosphorylation of
IRS-1 (Figure 5). In these experiments, interactions
between HDAC2 and IRS-1 were apparently weaker in
cells treated in the presence of TSA. This is not a consistent
phenomenon, and occurs to varying degrees in our
experiments (unpublished data). However, TSA has been
reported to break other cellular HDAC-phosphatase com-
plexes [41], so the effect here on HDAC2 and IRS-1 is not
unprecedented. Treatment of cells with PMA and DesCoA
did not lead to significantly greater effects, indicating that
the two compounds share a common mechanism of
reducing insulin signalling. Thus, inhibition of intracellu-
lar lysine acetylation accompanied by interactions
between IRS-1 and HDAC2 leads to compromised insulin
signalling, which can be overcome by inhibition of HDAC
activity. Casein kinase II is an enzyme that has been
shown to regulate the ability of HDAC2 to form oligo-
meric complexes both positively and negatively [32].
Interestingly, treatment with an inhibitor of casein kinase
II (5,6-dichloro-1-β -D-ribofuranosylbenzimidazole) did
not induce binding between IRS-1 and HDAC2 (Kaiser &
James, unpublished) and had no effect on insulin
signalling.
To ascertain if more distal insulin signalling was also
enhanced, we examined the activation of protein kinase B
(PKB) by western blotting, using an antibody against PKB
phosphorylated on serine 474; this phosphorylation is
induced in a PI3K-sensitive manner resulting in enhanced
protein kinase activity. The data showed that PMA
treatment reduced the activation of PKB by 50% (Figure 6
lane 3), whereas with pre-treatment with TSA, the
response was 80% of control (Figure 6 lane 5). Thus, TSA-
mediated increases in lysine acetylation of IRS-1 led to vir-
tual restoration of PKB activation by insulin in PMA-
treated cells. Interestingly, the PKB response in the pres-
ence of TSA and PMA (but no insulin, Figure 6 lane 4)
showed significantly higher basal activation of PKB than
in unstimulated cells. We speculate that this is due to the
recently described ability of HDAC inhibitors, including
TSA, to activate PKB through an unknown mechanism
[47]. Thus, the increased response of cells to insulin in the
presence of TSA (Figure 6 lane 5) may represent a summa-
tion of the effects of TSA alone and insulin. One candidate
mechanism for the reported activation of PKB by HDAC
inhibition is via increased acetylation of IRS-1 leading to
enhanced basal PI3K activity and enhanced PKB activity.
We could not, however, detect increases in basal tyrosine
phosphorylation of IRS-1 in the presence of TSA without
insulin (Figure 4 lane 4), suggesting that, if this is indeed
Inhibition of HAT activity inhibits insulin signalling Figure 5
Inhibition of HAT activity inhibits insulin signalling. 
MCF-7 cells were treated with PMA, TSA and DesCoA (10 
nM) in the indicated combinations for four hours prior to 
stimulation with insulin for 10 minutes. IRS-1 was immuno-
precipitated and western blotted for the presence of IRS-1 
itself, HDAC2 and phosphotyrosine. The graph shows aver-
age data for phosphotyrosine from three independent exper-
iments (± SEM) normalised to the response to insulin alone.
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part of the mechanism of activation of PKB by HDAC
inhibition, it is beyond the limits of detection. Such a pos-
sibility is not without precedent. We have previously
reported the ability of a non-specific protein tyrosine
phosphatase inhibitor to increase PI3K-dependent
glucose transport in muscle cells in culture without being
able to detect changes in basal tyrosine phosphorylation
of the insulin receptor or IRS-1 [48]. Thus, it remains pos-
sible that HDAC inhibition by TSA leads to enhanced PKB
phosphorylation through small changes in IRS-1
phosphorylation.
A major functional response downstream of the PI3K arm
of insulin signal transduction is increased glucose trans-
port mediated by the GLUT4 transporter. We sought to
examine the effects of TSA on glucose transport in rat L6
myotubes to see if the enhanced insulin signalling medi-
ated by TSA treatment of cells translated into increased
glucose uptake. We found that treatment of L6 myotubes
with PMA resulted in increased basal glucose transport
and had no effect on insulin-stimulated glucose transport
(Kaiser & James, unpublished). Such effects are in line
with data presented for rat epitrochlearis muscle [49] and
indicated that L6 cells do not exhibit a clear insulin-resist-
ance phenotype after PMA treatment, at the level of
glucose transport. We also have similar observations in
the human neuroblastoma cell line SHSY-5Y, which dem-
onstrates insulin-stimulated glucose uptake [50]. Phorbol
ester treatment of these cells increased basal glucose trans-
port but in contrast to data in L6 cells, also inhibited
insulin-stimulated glucose transport (Kaiser and James,
unpublished). We have therefore not been able to distin-
guish an effect of TSA on GLUT4-mediated glucose trans-
port owing to the large PMA-stimulated increases in
insulin-independent glucose transport (presumably
mediated by GLUT1), and are at present analysing other
cells for their response to phorbol ester treatment. Inter-
estingly, Takigawa-Imamura et al. [51] recently showed
that several HDAC inhibitors increase glucose transport in
muscle cells in culture. Although the treatment regimens
with these inhibitors in these experiments were chronic,
the data show that inhibition of HDAC activity enhances
glucose transport. Molecular mechanisms behind this
effect could be several, including enhanced insulin signal-
ling through increases in intracellular protein acetylation.
TSA is an efficacious inhibitor of all class I and class II
HDAC enzymes, with a potency in the low nanomolar
range. To ascertain whether specific inhibition of HDAC2
activity is able to enhance insulin signalling in otherwise
non-permissive conditions (PMA treatment), we used
RNA interference to reduce HDAC2 activity specifically.
MCF-7 cells were transiently transfected with a 21 base
RNA duplex oligonucleotide against HDAC2 which
reduced the HDAC2 protein content of the cells by
approximately 70% (Figure 7). This was associated with a
greater than three-fold increase in lysine acetylation of
IRS-1. Furthermore, insulin-stimulated tyrosine phospho-
rylation of IRS-1 was increased 1.5-fold in RNAi-treated
cells (Figure 7). A second RNAi oligonucleotide against
HDAC2 was found to be much less efficient in silencing,
exerting no effect on HDAC2 expression at 25 nM (corre-
sponding to 80 pmol, see Methods section). Control
experiments with this oligonucleotide at concentrations
when HDAC2 expression was unaffected, showed that
insulin-stimulated tyrosine phosphorylation of IRS-1 was
not affected (data not shown), indicating that specific
reductions in HDAC2 after RNAi treatment were the main
cause of enhanced insulin signalling and IRS-1 acetyla-
tion. These data showed that specific reductions in
HDAC2 activity in MCF-7 cells induced similar changes in
IRS-1 regulation as treatment with TSA and that HDAC2 is
an integral component of phorbol ester-induced insulin
unresponsiveness in cells. The increase in lysine acetyla-
tion and tyrosine phosphorylation was arguably not as
marked in RNAi-treated cells as in cells treated with TSA.
An interpretation of these data could be that other mem-
bers of the HDAC family are also involved in the processes
Distal insulin signalling is enhanced by increased IRS-1 lysine  acetylation Figure 6
Distal insulin signalling is enhanced by increased IRS-
1 lysine acetylation. MCF-7 cells were treated with PMA, 
TSA and insulin as for Figure 4 and lysates were western 
blotted for the presence of PKB phosphorylated on serine 
474. The graph shows average data from three independent 
experiments (± SEM) normalised to the insulin response 
alone.
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leading to insulin resistance. We have found that HDAC1
does co-immunoprecipitate with IRS-1 from MCF-7 cells
but its regulation is different, with no significant changes
in the association by prolonged insulin stimulation or by
PMA treatment of the cells (Kaiser & James, unpublished)
suggesting that whatever the involvement of other
HDACs, HDAC2 is central to the observed changes in
insulin signalling.
The data we present here imply that treatment of insulin-
resistant or diabetic animals with inhibitors of HDAC2
should increase insulin responsiveness. We attempted to
assess the effects of TSA on insulin sensitivity in ob/ob
mice. The animals were divided into two groups: vehicle
(DMSO) and TSA (0.1 mg/kg) and treated subcutaneously
for three days. At the same time as drug injection, all food
was withdrawn from the animals and 4 hours later, blood
was collected from the tail vein for blood glucose and
plasma insulin analysis. On the third day, an insulin
tolerance test (ITT) was performed 4 hours after adminis-
tration of the drug. After 24 hours, fasting blood glucose
tended to be lower in treated animals than vehicle
Specific inhibition of HDAC2 enhances insulin signalling Figure 7
Specific inhibition of HDAC2 enhances insulin signalling. MCF-7 cells were transfected with short inhibitory RNA oli-
gonucleotides (80 and 160 pmol as indicated) for four hours and cultured a further 48 hours prior to treatment with PMA (10 
ng/ml for 4 hours) and stimulation with insulin (100 nM) for 10 minutes. IRS-1 was immunoprecipitated and western blotted for 
the presence of HDAC2, phosphotyrosine, acetyl lysine and IRS-1 itself. The graphs show average data (± SEM) for 3–5 inde-
pendent experiments, normalised to the insulin response alone. P-Y: phosphotyrosine.
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controls, but after three days no difference was evident.
Furthermore, we were unable to detect a change in insulin
sensitivity after drug treatment during the ITT on day 3
(Kaiser, Warpman & James, unpublished). In addition, no
changes in lysine acetylation of IRS-1 were observed, indi-
cating that the lack of effect on insulin sensitivity could be
due to the inability of TSA to work through the molecular
mechanism of increasing IRS-1 acetylation. TSA is rapidly
metabolised by liver cells in culture in two stages, initially
by reduction to the imide followed by demethylation,
leading to inactive metabolites [52]. It is therefore proba-
ble that the compound was rapidly metabolised by
hepatic phase I metabolic processes in these experiments
so that it was unable to exert pharmacodynamic effects on
the animals. The poor bioavailability of TSA [53] has led
to its discontinuation as a clinical candidate for the treat-
ment of human disease and the possibility of testing the
insulin sensitizing effects of HDAC inhibition must await
the availability of a drug with better pharmacokinetics.
Furthermore, HDACs are not redundant, but have specific
expression patterns and functions. Therefore, it is of great
importance to develop specific HDAC-inhibitors to be
able to assess their respective contributions to increases in
insulin sensitivity in vivo.
The mechanism whereby lysine acetylation of IRS-1 leads
to increased tyrosine phosphorylation by the insulin
receptor is not known. Time course experiments, in which
cells were stimulated with insulin for one to ten minutes,
showed that the kinetics of IRS-1 phosphorylation were
the same, irrespective of pre-treatment of cells with TSA
(Kaiser & James, unpublished). However, the IRS-1 tyro-
sine phosphorylation signal was greater at all times in
cells treated with TSA, suggesting that lysine acetylation of
IRS-1 simply increases the amount of phosphorylated IRS-
1. It has recently been shown that lysine acetylation pro-
tects the transcription factor SREBP1C from ubiquitina-
tion and degradation via the proteasomal pathway by
competing for the same lysine residues. IRS-1 has also
been shown to be degraded via ubiquitination and subse-
quent proteasomal degradation [21]. We investigated the
influence of lysine acetylation of IRS-1 on ubiquitination
by blotting immunoprecipitates of IRS-1 from cells for the
presence of ubiquitin (Fig 8). The data showed that in the
absence of PMA, IRS-1 was only slightly ubiquitinated,
whereas in cells treated with PMA, this was markedly
increased. The molecular mass of both bands of the IRS-1
doublet increased after PMA treatment, spanning 132 kD
to 145 kD, presumably due to the addition of ubiquitin
molecules. TSA did not influence PMA-induced ubiquiti-
nation of IRS-1. These data therefore indicate that
increases in IRS-1 phosphorylation after its lysine acetyla-
tion are not the result of increasing the concentration of
the protein by preventing its degradation. Interestingly, a
protein called PH domain interacting protein (PHIP) was
recently described that selectively binds in vitro and con-
stitutively associates in cells to the PH-domain of IRS-1
[54]. PHIP is not itself a substrate of the insulin receptor
but rather a ligand of the IRS-1 PH-domain that serves to
link IRS-1 to the insulin receptor and enhance its phos-
phorylation. PHIP contains two bromodomains located
in tandem in the centre of the molecule [55]. Considering
the fact that IRS-1 is acetylated and that bromodomains
can interact specifically with acetylated lysine [56], the
mode of interaction between PHIP and IRS-1 could be
through the bromodomains, providing a molecular
mechanism that explains why the increased acetylation of
IRS-1, after TSA treatment, is accompanied by a higher
level of tyrosine phosphorylation of IRS-1 despite the
insulin resistant state. We have sought to test this hypoth-
esis by blotting immunoprecipitates of IRS-1 for PHIP but
have been unable to distinguish a specific band corre-
sponding to PHIP using the antibodies that are available
commercially.
Conclusions
In this study, we have identified a previously undescribed
interaction between IRS-1 and HDAC2 in the cytosolic
compartment of cells. The interaction is observed both in
vitro and in vivo during conditions of compromised insu-
lin signalling, as seen by reductions in insulin-stimulated
IRS-1 tyrosine phosphorylation and PKB activation and
increased phosphorylation of the negative regulatory
phosphorylation site, serine 312. Our data indicate that it
is the interaction with HDAC2 itself rather than its
catalytic activity that is integral to the insulin unrespon-
siveness that ensues. Furthermore, our data show that IRS-
1 is a lysine-acetylated protein, a previously unidentified
IRS-1 ubiquitination is not altered by acetylation Figure 8
IRS-1 ubiquitination is not altered by acetylation. 
MCF-7 cells were treated with PMA, TSA and insulin as 
described for Figure 4 and immunoprecipitated IRS-1 was 
western blotted for the presence of ubiquitin (upper panel) 
and IRS-1 (lower panel). The molecular mass of the immuno-
precipitated ubiquitinated protein and IRS-1 protein is 
indicated.
TSA +      +      +       - - -
PMA  +      +      - +       - -
Insulin +       - +      +       - +       
IRS1
ubiquitin
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post-translational modification of IRS-1, and that
increases in the level lysine acetylation of IRS-1 result in
improved insulin signal transduction. Increases in IRS-1
acetylation can be achieved pharmacologically (with TSA)
or by ablation of HDAC2 specifically by use of RNAi. Out
data therefore indicate that a new dimension to the phys-
iology and pathophysiology of insulin sensitivity and
insulin resistance involves changes in the degree of lysine
acetylation of IRS-1 and that specific small molecule
inhibitors of HDAC2 activity could represent novel thera-
peutics for the treatment of diseases that centre around
insulin resistance, such as type 2 diabetes and obesity.
Methods
Yeast two hybrid screening
The CytoTrap™ (Stratagene) yeast two-hybrid system was
used to discover protein-protein interactions in the cyto-
plasm of yeast cells. Interactions were detected by recruit-
ment to the cell membrane of the human Sos (hSos) gene
product, which activates the Ras pathway. The yeast strain
used (cdc25H) harbours a temperature sensitive mutation
in the cdc25 gene, the yeast homologue for hSos, which
means that the cells can grow at 25°C but not at 37°C
unless rescued with a protein-protein interaction. A
human foetal brain plasmid cDNA library (Stratagene),
harboured in the pMyr vector (with a myristylation signal
to direct and anchor proteins in the membrane), was used
as "prey" and the sub-cloned full length IRS-1 gene in the
pSos vector was used as "bait". When prey and bait pro-
teins interact the hSos is brought into close proximity to
Ras and subsequently the yeast survive and are selected by
growth at 37°C. The IRS-1/HDAC2 interaction rescued
growth at 37°C in this way. The corresponding pMyr yeast
plasmid was isolated and co-transformed with the pSos
bait construct to perform false positive tests.
HDAC2 was full length cloned using RACE cDNA
obtained from human heart tissue together with gene spe-
cific primers and the Advantage 2 polymerase mix (Clon-
tech). With the purpose of mapping the interaction site of
HDAC2 on IRS-1 we used the Matchmaker 3 yeast two-
hybrid system (Clontech). This is a GAL4-based two-
hybrid system that provides a transcriptional assay for
detecting specific protein-protein interactions in yeast.
Two nutritional markers and one enzymatic reporter gene
were used to detect interactions. Different domains of IRS-
1 (PH domain, residues 1–155, the PH-PTB domains, res-
idues 1–578 and the PH-PTB-pre-C-terminal domains,
residues 1–895, obtained by PCR) were sub-cloned into a
"bait" vector (pGBKT7), fused to the DNA-binding
domain of GAL4. Full length HDAC2 was sub-cloned into
the "prey" vector (pGADT7), fused to the activation
domain of GAL4. Cell growth on medium lacking the two
nutritional markers was used as a readout of the interac-
tion between the predator and prey.
In vitro transcription-translation
In order to confirm the IRS-1/HDAC2 interaction in vitro,
we used a coupled transcription/translation system
(Promega) comprising a rabbit reticulocyte lysate solu-
tion with RNA polymerase, nucleotides, salts, a ribonucl-
eoside inhibitor, and [35S]-methionine (Amersham
Biosciences) to allow detection of translated proteins.
Since the prey vector pMyr already contains a T7 pro-
moter, this was used directly in the system. However, the
bait vector pSos lacks a T7 promoter and thus the IRS-1
gene was subcloned into a T7-containing vector (pGBKT7;
Clontech) to permit transcription. The individually tran-
scribed and translated proteins were mixed and co-immu-
noprecipitated with anti-IRS-1 antibodies (Upstate
Biotechnologies) and subsequently analysed by polyacry-
lamide gel electrophoresis (4–12%). The gel was dried
analysed by phosphorimagery.
Cell culture
The human breast adenocarcinoma cell line MCF-7 was
cultured in a mixed medium of Dulbecco's Modified Eagle
Medium with nutrient mixture F12 (Invitrogen) lacking
phenol red with 10% Foetal Bovine Serum (Gibco). At
near confluency, cells were starved of serum for 16 h and
subsequently treated with IGF-1, insulin, PMA (phorbol
myristic acid; Sigma) or TSA (Trichostatin A; Sigma), or
combinations thereof, for different lengths of time as indi-
cated in individual figures. Cells were harvested in hypot-
onic cell lysis buffer comprising 20 mM Hepes, pH 7.6,
20% glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.1% NP40, 25 mM NaF, 25 mM β-glycerophos-
phate, 1 mM DTT, 1 mM Na-orthovanadate and protease
inhibitors.
Western blot assays
Cell lysates were cleared by centrifugation at 16000 g for
10 min at 4°C, and protein content was determined using
the Bradford method (BioRad). For immunoprecipita-
tions, matched amounts of protein were incubated with
primary antibody (amount used as recommended by the
manufacturer or empirically determined) for 2 h at 4°C
followed by addition of 20µl of protein A/G agarose sus-
pension (Santa Cruz) for 1 h at 4°C with rotating tube.
After washing (3 times with high salt (500 mM NaCl) and
twice with isotonic buffer), beads were heated with SDS-
PAGE sample buffer for 10 minutes at 70°C and proteins
were resolved by 4–12% gradient SDS-PAGE. After blot-
ting, membranes were blocked in 5% non-fat dried milk
in Tris-buffered saline containing 0.1% Tween 20 for 1 h
prior to addition of the primary antibody. After incuba-
tion with secondary horseradish peroxidase-conjugated
antibody, protein bands were visualised using enhanced
chemiluminescence (ECL-plus detection kit, Amersham
Biosciences).BMC Biology 2004, 2:23 http://www.biomedcentral.com/1741-7007/2/23
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Antibodies used were anti-IRS-1 (Upstate, cat. no 06–
248); anti-HDAC2 (Santa Cruz, cat. no. sc-9959 and sc-
6296); anti-phosphotyrosine (Santa Cruz, cat. no. sc-
7020); anti-acetyl lysine (Cell Signalling, cat. no. 9681);
anti-ubiquitin (Santa Cruz, cat. no. sc-6085 and sc-9133);
anti-phospho-serine 307 IRS-1 (Upstate, cat. no. 07–
247), HRP-conjugated anti-mouse IgG (Amersham Bio-
sciences, cat. no. NA931V); HRP-conjugated anti-goat IgG
(Dako cat. no. PO449) and HRP-conjugated anti-rabbit
IgG (Upstate, cat. no. 12–348).
RNA interference
Double stranded RNA duplexes corresponding to amino
acids from the C-terminal part of human HDAC2
(5'CAGCUCAGCAACCCCUGAAtt3') were annealed and
transfected into human MCF-7 cells (Lipofectamine 2000
from Invitrogen was used as transfection agent): The effect
of RNAi on HDAC2 expression and on insulin dependent
IRS-1 tyrosine phosphorylation was measured after 48
hours. A second oligonucleotide
(5'GGAGCAAAGAAAGCUAGAAtt3') was found to be
non-silencing at a dose of 80 pmol, in contrast to the
silencing oligonucleotide above, and was used in control
experiments showing that no effect on IRS-1 phosphoryla-
tion or acetylation was observed (data not shown).
Animal experiments
Male 8-week old ob/ob mice were obtained from Bom-
hultsgard, Denmark and housed according to standard
procedures. C57/bl6 genotype control mice were
obtained from Scanbur BK AB (Sollentuna, Sweden).
PTP1B knockout animals on a balb/cJJ background were
purchased from McGill University, Montreal, Canada.
Balb/cJJ genotype controls were obtained from Scanbur
BK AB. In our hands, balb/cJJ mice are generally a healthy
mouse strain that breeds well. In side-by-side experi-
ments, the mice are more insulin sensitive than C57/bl6
mice whilst being less insulin sensitive than the PTP1B
knockout animals on the same genetic background. The
animals are somewhat smaller than C57/bl6 mice and
have a relatively high body fat content.
For compound treatment experiments and insulin toler-
ance tests, animals were divided into two groups: vehicle
(1% DMSO sub-cutaneous injection (s.c.), n = 15 and TSA
0.1 mg/kg s.c., n = 15) and subsequently treated s.c. at
09.00 h for three days. At the same time as injection, all
food was withdrawn from the animals. Four hours later,
blood was collected from the tail vein for blood glucose
and plasma insulin analysis. On the third day, an insulin
tolerance test (ITT) was performed 4 h after administra-
tion of the drug. ITT: insulin (actrapid 0.5 U/kg) was
administered i.p. Following insulin administration, blood
samples were collected after 15, 30, 60, 120 and 180 min
from the tail vein for glucose analysis. Animals were then
sacrificed and livers were dissected and immediately fro-
zen in liquid nitrogen and stored at -70°C. All experi-
ments were performed in accordance with permission
from the local Swedish ethics committee and the com-
pany Pharmacology ethics review team.
For western blotting of liver proteins, frozen liver was
powdered finely under liquid nitrogen using a pestle and
mortar pre-cooled to -70°C. Powdered liver (1 g) was
homogenized at 4°C using a Polytron in 3 ml of homog-
enisation buffer (4 mM EDTA, 50 mM NaF pH 8.0, 1 mM
Na-orthovanadate, 1µM okadaic acid, 0.1% (v/v) 2-mer-
captoethanol, with protease inhibitor cocktail). The
homogenates were centrifuged at 13000 × g for 10 min-
utes at 4°C and the supernatant removed and used imme-
diately for Western blot analysis or snap frozen in aliquots
at -70°C until needed.
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